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Introduction: In this study, we evaluated the clinical relevance of serum drug levels and antidrug antibodies
(ADAbs) with regard to response to treatment, as well as to relapse upon treatment discontinuation, in peripheral
spondyloarthritis (pSpA) patients treated with adalimumab.
Methods: The study included 26 pSpA patients treated with adalimumab for either 12 weeks (n = 12) or 24 weeks
(n = 14) in a randomized controlled trial. Patients achieving inactive disease measured by Ankylosing Spondylitis
Disease Activity Score (ASDAS) at the end of the treatment period were classified as responders. Clinical
characteristics, serum trough adalimumab levels and ADAbs were assessed at the end of the treatment period and
at follow-up (upon relapse or, in absence of relapse, at 16 weeks after discontinuation).
Results: Serum adalimumab levels measured 2 weeks after the last adalimumab administration ranged from <0.002
to 23.0 μg/ml, with a median of 11.5 μg/ml. These levels were associated with neither response to treatment or
disease activity measurements at the end of treatment nor with the occurrence of relapse and time to relapse after
discontinuation of treatment. Antiadalimumab ADAbs were present in 23% of the patients at end of treatment and
in 35% at follow-up after treatment discontinuation, indicating that ADAbs were masked by the presence of the
drug in some patients. However, ADAbs at the end of treatment and at follow-up were not different between
responders and nonresponders and were not associated with relapse upon discontinuation of treatment.
Conclusions: There is no clear association between adalimumab serum levels or antiadalimumab ADAbs with
clinical response to treatment or with relapse upon treatment discontinuation in pSpA.
Trial registration: Netherlands Trial Register ID: NTR1806 (registered 7 May 2009)Introduction
Tumour necrosis factor (TNF) inhibition is a highly effect-
ive treatment for axial and peripheral spondyloarthritis
(SpA) [1-5]. However, a significant proportion of patients
fails to respond or does not tolerate the treatment because
of side effects. The reasons for nonresponse or for intoler-
ance are multiple, potentially including the development* Correspondence: d.l.baeten@amc.uva.nl
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article, unless otherwise stated.of antidrug antibodies (ADAbs) directed towards the TNF
blocker. It has been proposed that ADAbs may reduce
therapeutic responses, either by increasing the clearance
of the TNF inhibitor [6] or by direct neutralisation of the
functional part of the drug [7]. Accordingly, authors of re-
cent reviews have suggested that monitoring of serum
drug levels and ADAbs would be a promising tool for per-
sonalised cost-effective usage of biological therapies in
immune-mediated inflammatory diseases (IMIDs) [8,9].
Most studies on the immunogenicity of TNF blockers
have been performed in rheumatoid arthritis and Crohn’sd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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have yielded conflicting results. Regarding infliximab and
adalimumab, some research groups have reported that
ADAbs towards these TNF inhibitors are associated with
decreased clinical response and increased risk of hyper-
sensitivity reactions [10-16], whereas others have not
found this association and have even concluded that
serum anti-TNF drug levels are not associated with re-
sponse to treatment [17,18]. For etanercept, these ADAbs
have not been detected, and it has been shown that the
serum drug levels are similar in responders and nonre-
sponders [19]. Recently, golimumab ADAbs did not ap-
pear to have a major role in treatment success or failure
[20,21]. Moreover, the authors of a recent meta-analysis of
anti-TNF ADAbs in various IMIDs concluded that there
was no relevant association of ADAbs with efficacy in
SpA [22]. This corresponds to the clinical experience
that treatment failure after TNF blockade is similar
among the various TNF blockers [23,24], both the ones
which do and those that do not cause the development
of ADAbs according to the results of the aforemen-
tioned studies [10-21].
These conflicting results may be related to the diversity
of methods used and the timing of the measurement to
evaluate the ADAbs, as well as to the fact that the pres-
ence of detectable serum drug levels may mask the detec-
tion of ADAbs [8,9]. The latter issue can be avoided by the
use of novel assay methods [25] and/or by assessing the
ADAbs several weeks after stopping the TNF inhibitor. In
this study, we assessed the potential clinical relevance of
serum drug levels and ADAbs measured at the end of the
treatment period as well as at a drug-free follow-up exam-
ination after a double-blind, placebo-controlled, random-
ized clinical trial (RCT) with adalimumab in patients with
peripheral SpA (pSpA) [5]. We correlated these serum
levels with both clinical response at the end of treatment
and relapse upon discontinuation of the TNF inhibitor.
Methods
Study patients
Twenty-six patients from our RCT with adalimumab in
peripheral arthritis in SpA who did not fulfil the criteria
for ankylosing spondylitis (AS) or psoriatic arthritis (PsA)
[5] were included in this study. The patients fulfilled the
European Spondyloarthritis Study Group (ESSG) criteria
[26] and/or the Amor et al. criteria [27] and had active
disease at the time of inclusion. They were treated with ei-
ther placebo (n = 12) or adalimumab (n = 14) for 12 weeks,
followed by a 12-week open-label phase with adalimumab
for all patients [5]. After this period, adalimumab was dis-
continued. Patients were allowed to continue treatment
with nonsteroidal anti-inflammatory drugs (NSAIDs), corti-
costeroids (≤10 mg/day prednisone or equivalent), metho-
trexate and sulfasalazine at a stable dosage throughout thestudy. After discontinuation of the TNF inhibitor, patients
were prospectively followed for 16 weeks and seen for a re-
lapse visit upon worsening of symptoms or, in the absence
of relapse, at the 16-week follow-up visit. The following dis-
ease activity parameters were measured: patient’s and physi-
cian’s global assessment of disease activity, 68/66 tender
joint count (TJC) and swollen joint count (SJC), Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI) score,
Ankylosing Spondylitis Disease Activity Score (ASDAS),
erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP) level. Responders were defined as patients
achieving inactive disease based on ASDAS at the end of
treatment [28]. Relapse was defined as an increase of at
least one swollen joint or an increase by at least two points
in the patient’s or physician’s global assessment of disease
activity or BASDAI score [29]. Fourteen patients (53.8%)
reached ASDAS-defined inactive disease at the end of the
treatment period. Nineteen patients (73.1%) had a disease
relapse within 16 weeks after discontinuation of adalimu-
mab, with a mean time to relapse of 10.0 ± 3.2 weeks. The
characteristics of the patients have been published previ-
ously [29]. Written informed consent was obtained from
each patient before study-related procedures were per-
formed, and the study was approved by the Medical Ethics
Committee of the Academic Medical Center/University of
Amsterdam.
Assessment of serum adalimumab levels
Serum samples were obtained 2 weeks after the last ada-
limumab administration (n = 26) and at follow-up (upon
relapse or 16 weeks after discontinuation in the absence
of relapse (n = 25). Trough serum adalimumab concentra-
tions were measured using an enzyme-linked immuno-
sorbent assay (ELISA) developed by Wolbink et al. as
previously described and as accredited by the Dutch Ac-
creditation Council/Dutch Accreditation Board for Medical
Laboratories (RvA/CCKL) according to the International
Standardization Organization (ISO) guideline ISO17025
[30]. The detection limit of the assay is approximately
0.001 μg/ml; serum adalimumab levels <5.0 μg/ml were
designated low, as previously described [15,30].
Assessment of antibodies against adalimumab
The same serum samples were analysed by radioimmuno-
assay (Sanquin) to detect the presence of antiadalimumab
antibodies as previously described [30]. Dilution of 1 μl of
serum in phosphate-buffered saline/0.3% bovine serum al-
bumin (pro analysi buffer) was followed by overnight in-
cubation with 1 mg of Sepharose-immobilized protein A
(GE Healthcare, Chalfont St Giles, UK) in a final volume
of 800 μl. Next, the samples were washed with phosphate-
buffered saline 0.005% polysorbate. The antiadalimumab
binding was determined by overnight incubation with
20,000 disintegrations per minute (dpm (approximately
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diluted in Freeze buffer (Sanquin, Amsterdam, the
Netherlands). Unbound label was removed by washing,
and protein A–bound radioactivity was measured. Antia-
dalimumab levels were expressed in arbitrary units (AU;
1 AU ≈ 12 ng) using a serum containing antiadalimumab
as standard. The mean cutoff value derived from 100
healthy donors was set at 12 AU/ml.Statistical analysis
The data are presented as medians and interquartile
ranges (IQRs). Mann–Whitney U tests were used to com-
pare differences in serum levels in cases of unpaired sam-
ples, and Wilcoxon signed-rank tests were performed in
cases of paired samples. χ2 tests were used for categorical
variables. Logistic regression analyses were conducted to
examine associations between the ASDAS response, re-
lapse status and trough serum adalimumab and antiadali-
mumab ADAb levels. Correlations between the serum
measurements and the clinical disease activity measure-
ments were assessed using Spearman’s correlation tests.
All statistical tests were two-sided, and P-values <0.05
were considered statistically significant.Results
Clinical response to treatment and relapse after anti-TNF
treatment discontinuation are independent of trough
serum adalimumab levels
Trough serum adalimumab levels at the end of the
treatment period (2 weeks after the last injection)
ranged from <0.002 to 23.0 μg/ml (median = 11.5 μg/ml).
Seven patients (26.9%) had serum adalimumab levels
<5.0 μg/ml. Levels were not different between patients
treated with adalimumab for 12 or 24 weeks (P = 0.292)
(Figure 1A). There were no significant differences in
trough serum adalimumab levels between responders
(median = 12.6 (IQR = 7.3 to 16.2) μg/ml) and nonre-
sponders (9.3 (3.1 to 14.5) μg/ml) as defined by the
achievement of inactive disease defined by ASDAS (P =
0.237) (Figure 1B). Serum adalimumab levels also did
not correlate with end-of-study disease activity parame-
ters such as patient’s global assessment (Figure 1C) and
physician’s global assessment of disease activity, TJC,
SJC, BASDAI score, ASDAS, ESR (data not shown) and
CRP level (Figure 1D). Moreover, adalimumab levels at
the end of treatment were not different between pa-
tients with vs. without subsequent relapse upon discon-
tinuation of therapy (P = 0.931) (Figure 2A) and were
not correlated with time to relapse (P = 0.984) (Figure 2B).
Taken together, these data indicate that the amplitude
and/or duration of clinical response to adalimumab in
pSpA patients are not related to trough serum adalimu-
mab levels.Clinical response to treatment and relapse after anti-TNF
treatment discontinuation are independent of presence
of antiadalimumab antidrug antibodies
At the end of the treatment period, 6 (23.1%) of 26 patients
tested positive for serum antiadalimumab ADAbs: 4 were
clearly positive, with titres ranging from 89 to 2,320 AU/ml,
and 2 were borderline positive, both with a titre of 15 AU/ml.
The presence of detectable antiadalimumab ADAb levels
was similar between patients treated with adalimumab for
12 weeks (4 (33.3%) of 12 patients) or for 24 weeks (2
(14.3%) of 14 patients) (P = 0.250) (Figure 3A) and be-
tween responders (3 (21.4%) of 14 patients) and nonre-
sponders (3 (25.0%) 12 patients) (P = 0.829) (Figure 3B).
The antiadalimumab ADAb titres did not correlate with
the various disease activity measurements (data not
shown). Finally, the number of patients who tested posi-
tive for antiadalimumab ADAbs was not different between
those with vs. without subsequent relapse upon discon-
tinuation of therapy (P = 0.518) (Figure 4A), nor was there
a difference in time to relapse (P = 0.488) (Figure 4B). As
for the trough serum adalimumab levels, our data do not
provide any evidence that antiadalimumab ADAbs have a
significant impact on the amplitude and/or the duration
of clinical response to adalimumab in pSpA.
Antiadalimumab ADAbs can be masked by presence of
adalimumab; ‘unmasked’ antiadalimumab ADAbs do not
correlate with clinical response to treatment
As several factors can bias the measurement and/or inter-
pretation of ADAbs, we conducted additional analyses to
assess the potential clinical relevance of these antibodies.
First, there was a negative correlation between the antia-
dalimumab ADAb titres and serum trough adalimumab
levels (R = −0.709, P < 0.001). This may be explained by
the fact that ADAbs contribute to the clearance of the
drug or, alternatively, by the fact that serum adalimumab
levels may interfere with the measurement of the ADAbs
[8,9]. To investigate the latter possibility, we obtained add-
itional serum samples from 25 of 26 patients at a median
follow-up of 10.1 (IQR = 8.3 to 14.0) weeks after interrup-
tion of the adalimumab treatment. At this time point, the
median serum adalimumab level was 1.7 (IQR = 0.2 to 4.4)
μg/ml, which was significantly lower than the level at the
end of treatment (P < 0.0001) (Figure 5A). Measurement
of antiadalimumab ADAbs at the same time point, which
allowed us to exclude interference of circulating adalimu-
mab levels, showed that the four patients with high
ADAbs at the end of treatment maintained high ADAb
levels after interruption of treatment, whereas the titres
tended to increase over time in the three patients with low
ADAb titres at the end of treatment (Figure 5B). Addition-
ally, three patients without detectable ADAbs at the end
of treatment had titres between 15 and 57 AU/ml at
follow-up, confirming that low to intermediate levels of
Figure 1 Clinical response to treatment is independent of trough serum adalimumab levels. Trough serum adalimumab levels at the end of
treatment (2 weeks after the last injection) were not different between patients treated with 12 or 24 weeks of adalimumab (A) or between responders
and nonresponders (B) Median (interquartile range). Also, there was no correlation between these drug levels and clinical disease activity parameters
such as patient’s global assessment of disease activity measured on a 100-mm visual analogue scale (VAS) (C) or C-reactive protein (CRP) level (D).
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mab. However, these ‘unmasked’ antiadalimumab ADAbs
were not different between responders (33.3% positive for
‘unmasked’ antiadalimumab) and nonresponders (40.0%
positive for ‘unmasked’ antiadalimumab) (P = 0.734) or be-
tween patients who did vs. those who did not experience
relapse after treatment discontinuation (42.1% and 16.7%,Figure 2 Relapse after treatment discontinuation is independent of tr
the end of treatment (2 weeks after the last injection) were similar between pa
tumour necrosis factor inhibitor (TNFi) (A) Median (interquartile range). Neitherrespectively; P = 0.258). The titres of the ‘unmasked’ADAbs
were not correlated with either the various disease activity
measurements or the time to relapse (data not shown).
Second, we investigated the effect of concomitant
treatment with disease-modifying antirheumatic drugs
(DMARDs) on ADAbs because this has been described
to reduce the frequency of ADAb formation [8,9,14,31].ough serum adalimumab levels. Trough serum adalimumab levels at
tients who did and those who did not relapse after discontinuation of the
was there a correlation between the drug levels and time to relapse (B).
Figure 3 Clinical response to treatment is independent of the presence of antiadalimumab antidrug antibodies. Antiadalimumab
antidrug antibodies (ADAbs) at the end of treatment, 2 weeks after the last injection, were not different between patients treated with 12 vs.
24 weeks of adalimumab (A) or between responders vs. nonresponders (B).
Figure 4 Relapse after treatment discontinuation is
independent of the presence of antiadalimumab antidrug
antibodies. Antiadalimumab antidrug antibodies (ADAbs) at the
end of treatment, 2 weeks after the last injection, were not different
between patients who did vs. those who did not relapse after
discontinuation of adalimumab (A). There was no difference in time
to relapse in patients who tested positive vs. those who tested
negative for antiadalimumab ADAbs (B) Median (interquartile range).
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difference in antiadalimumab ADAb positivity between
patients taking DMARDs (5 (33.3%) of 15 patients,) vs.
patients not taking DMARDs (1, (9.1%) of 11 patients)
(P = 0.147) (Figure 6A). Strikingly, this difference was no
longer present when we analysed the ‘unmasked’ antia-
dalimumab ADAbs: 5 (35.7%) of 14 patients who were
positive in the no-DMARDs group vs. 4 (36.4%) of 11
patients in the DMARDs group (P = 0.973) (Figure 6B).
Adalimumab levels and antiadalimumab antidrug
antibodies in patients with generalized drug reactions
Two patients developed a generalized skin reaction upon
initiation of adalimumab during the study. Both patients
were able to continue adalimumab treatment after admin-
istration of topical corticosteroids and treatment with oral
antihistamine. One of these patients had a low serum
trough adalimumab level (<0.002 μg/ml) and tested positive
for antiadalimumab ADAbs with a titre of 2,320 AU/ml.
The second patient had a serum trough adalimumab level
of 17.5 μg/ml and tested negative for antiadalimumab
ADAbs both at the end of the study and at follow-up after
interruption of treatment. Neither of these two patients
used concomitant DMARDs.
Discussion
In this study, we assessed the potential relevance of serum
drug levels and ADAbs on various aspects of clinical re-
sponse to adalimumab treatment in pSpA. The major find-
ings are that (1) trough serum adalimumab levels were
heterogeneous but did not correlate with clinical response
to treatment or relapse after anti-TNF treatment discon-
tinuation, (2) antiadalimumab ADAbs were found in one-
fourth of the patients but also did not correlate with clinical
response to treatment or relapse after discontinuation of
the TNF inhibitor and (3) low-titre ADAbs could be
masked by circulating adalimumab, but ‘unmasked’ADAbs
showed no clear relationship with clinical efficacy.
Figure 6 The effect of disease-modifying antirheumatic drugs on anti
after the last injection), antiadalimumab antidrug antibodies (ADAbs) were les
antirheumatic drugs (DMARDs) compared than in patients who did not use a
However, this difference disappeared when we assessed the ‘unmasked’ antia
Figure 5 Antiadalimumab antidrug antibodies can be masked
by the presence of adalimumab in serum. Trough serum
adalimumab levels (A) and antiadalimumab antidrug antibody
(ADAb) titres (B) at the end of treatment (2 weeks after the last
injection) and at follow-up (upon relapse or, in absence of relapse,
at 16 weeks after discontinuation). *P < 0.05 assessed by Wilcoxon
signed-rank test.
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immunogenicity of TNF inhibitors in various IMIDs, in-
cluding SpA, because the development of ADAbs towards
these TNF inhibitors are assumed to play a major role in
loss of response to treatment. The mechanism behind this
is thought to be either an increased clearance of the drug
or neutralization of the active component of the com-
pound [6,7]. This hypothesis is supported by researchers
in several studies of infliximab and adalimumab who re-
ported that treatment failure occurred more often in pa-
tients who tested positive for ADAbs [10-14]. However,
there is also evidence which is not in line with this con-
cept; in other studies of infliximab, investigators did not
find a relation between ADAbs and response to treatment
[17,18]. Moreover, in one of the studies in which re-
searchers found serum trough infliximab levels to be sig-
nificantly higher in responders than in nonresponders,
although statistical significance was reached, the difference
between these groups was very low (8.2 μg/ml vs. 6.3 μg/ml,
respectively) [12]. Whether such a small difference is
really clinically relevant is questionable. ADAbs towards
etanercept have not been found, nor is there an associ-
ation between serum drug levels and clinical effect [19].
Likewise, for golimumab, there is no clear relation be-
tween ADAbs and clinical efficacy [20,21]. Furthermore,
in a recent meta-analysis of various TNF inhibitors [22]
and the clinical experience of there being no difference in
efficacy or drug survival between the various TNF inhibi-
tors [23,24], the authors also questioned the clinical rele-
vance of anti-TNF ADAbs.
Several factors could be examined to develop an explan-
ation of these differences between the various studies.
First, not all TNF inhibitors are assumed to be equally im-
munogenic. For example, the soluble dimeric fusion pro-
tein etanercept has a less immunogenic structure because
only the fusion part of the molecule can contain immuno-
genic epitopes. Also, it is administered more frequentlyadalimumab antidrug antibodies. At the end of treatment (2 weeks
s often observed in patients who used concomitant disease-modifying
ny DMARDs, although this finding was not statistically significant (A).
dalimumab ADAbs at follow-up (B).
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more drug interference in ADAb detection [19]. How-
ever, this does not explain why researchers in different
studies of the same TNF inhibitor (for example, inflixi-
mab) have come to different conclusions [10-14,17,18].
Second, there may be differences among the different
SpA subtypes. However, even in studies of both the
same disease and the same TNF inhibitor (for example,
infliximab in AS), contradicting conclusions have been
drawn [10-12,17,18]. Hence, this could also not explain
why we and others [21] did not find a clinical associ-
ation with anti-TNF drug levels or ADAbs in pSpA,
whereas researchers in another study did conclude that
these factors had clinical relevance [15]. Third, there is
some variation in the size and duration of the studies,
but this did not influence the results with regard to
whether ADAbs did or did not have clinical relevance
[10-21]. Fourth, the use of DMARDs, especially metho-
trexate, has been described to decrease the immunogen-
icity of TNF inhibitor trough, a mechanism which is not
yet understood [8,9,14,31]. However, this is not in line
with the finding that the addition of methotrexate in the
management of SpA does not have an impact on the ef-
ficacy of the treatment [23,24,32] or on drug survival of
the TNF inhibitor [23,24]. In our present study, we in-
deed found fewer of ADAbs in patients using DMARDs;
however, this difference was no longer present when we
analysed the ‘unmasked ADAbs’. Fifth, the detection of
ADAbs is also influenced by the assay used. However,
the method used in our present study is the same as
that used in other studies [15,16], making it unlikely
that this is the explanation for the differences in results.
Seventh, the timing of the samples also influences the
measurement of ADAbs because the assays are sensitive
to drug interference, even when measured before the
next administration of the drug, when the drug levels
are the lowest [8,9]. Indeed, we show here that when
antiadalimumab ADAbs were measured at follow-up,
after discontinuation of the TNF inhibitor, more pa-
tients tested positive than when antiadalimumab
ADAbs were measured at the end of treatment. Previ-
ous researchers have reported that anti-TNF ADAb ti-
tres can decrease and increase over time, and vice versa
[10,15,33], causing a gradual increase in incidence over
time when ADAb status is presented cumulatively, but
not when assessed at each time point independently
[33]. This shows that the timing of the measurement
can influence the interpretation of ADAb status, making
it very difficult to make strong conclusions about the re-
lationship with clinical response and to apply ADAb
measurement in clinical practise.
The limited number of patients is a limitation of our
study. We thus cannot exclude that clinical correlation
with serum adalimumab levels and/or ADAbs would befound in larger patient cohorts. However, this would
imply that this association is weak and thus not relevant
anyway for treatment monitoring in individual pa-
tients. Also, in one small study in which researchers in-
vestigated whether the serum trough infliximab levels
modified therapeutic decisions in the management of
AS, no improvement in the control of disease activity
was found [34]. Similar efficacy and drug survival of
TNF inhibitors—those that induce ADAbs and those
which do not [23,24] —also raise questions about the
relevance of testing the immunogenicity of these drugs.
Although testing immunogenicity in clinical trials is
standard practise and may yield interesting scientific
insights, the real added value of the presence or ab-
sence of ADAbs in an individual patient in clinical
practise remains to be demonstrated.
Conclusions
The link between either serum adalimumab levels or
antiadalimumab ADAbs and clinical response or relapse
is not as strong as previously assumed. This argues
against the use of these parameters in monitoring drug
efficacy. Although treatment with adalimumab and
other TNF inhibitors is very successful overall in SpA,
future research has to be done to unravel factors which
can explain differences in clinical response to further
improve disease management by developing a personal-
ized and more cost-effective approach.
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